Pune, Sept. 01, 2022 (GLOBE NEWSWIRE) -- The Global Immunoglobulin Market is expected to clock US$ 23.1 billion by 2030, according to the latest report published by Growth Plus Reports.
The global immunoglobulin market has been analyzed from four perspectives: by products, applications, route of administration, and region.
Market Drivers
The rising prevalence of immunodeficiency diseases is the major driving factor of the global immunoglobulin market. Malnutrition is the most prevalent cause of immune deficiencies worldwide, however in developed nations, the majority of immune deficiencies are inherited, and they are often diagnosed in clinics as recurring or overwhelming illnesses in very young children. According to the NCBI (National Center of Biotechnology Information), in 2021, over 6 million people worldwide have primary immunodeficiencies, and 70 to 90 percent of them are unknown of the disease.
Download Exclusive Sample of Report @ https://growthplusreports.com/inquiry/request-sample/immunoglobulin-market/7774
Excerpts from ‘By Product’
The global immunoglobulin market is divided into Immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), Immunoglobulin E (IgE), and Immunoglobulin D (IgD) based on the product types. These agenta are used to treat a variety of neurological and immunological problems. Immunoglobulin G is the most common class of immunoglobulin and plays a crucial role in the humoral immune response, it is predominant immunoglobulin found in blood which make approximately 75% of serum antibodies. IgG are mostly recommended in multiple sclerosis, and rheumatoid arthritis. Additionally, these are present in lymph fluid, cerebrospinal fluid, and peritoneal fluid. Immunoglobulin A (IgA) is essential for maintaining the health of the gastrointestinal, respiratory, and genitourinary tracts' mucosa. In this capacity, IgA serves as the dominant immune system antibody. IgM is characterized as it is crucial for immune control and immunological tolerance. In addition, it acts as the first line of defense for the host against infections.
Excerpts from ‘By Applications’
Hypogammaglobulin, CIDP (Chronic Inflammatory Demyelinating Polyneuropathy), immunodeficiency illnesses, and myasthenia gravis are the major conditions where immunoglobulins are used. The market has been dominated by hypogammaglobulin. Hypogammaglobulin restricts antibody synthesis and arises from an infection by autoimmune disorder or a malignancy such as multiple myeloma. Immunoglobulins are widely used to treat chronic inflammatory demyelinating polyneuropathy (CIDP), and are the first line of therapy for this disease. Immunodeficiency diseases need a steady combination of immunoglobulin to reduce the frequency and severity of infections.
Ask here for more customization study@ https://growthplusreports.com/inquiry/customization/immunoglobulin-market/7774
Excerpts from ‘By Route of Administration’
The global immunoglobulin market is divided into intravenous and subcutaneous segments based on the mode of administration. The largest market share in the global market is taken by intravenous immunoglobulins. Intravenous immunoglobulins are used to treat primary immunodeficiency. IVIg (Intravenous immunoglobulin) is also used in increase of blood platelet count and to aid in the prevention of certain B-cell infections. Subcutaneous immunoglobulin administration segment is also anticipated to witness notable growth during the forecast period, as it is associated with a decreased risk of both systemic and limited harm as compared to intravenous therapy.
Excerpts from ‘Competitive Landscape’
Some of the prominent players operating in the global immunoglobulin market are:
- ADMA Biologics Inc
- Baxter International Inc
- Biotest AG
- Takeda Pharmaceutical Company
- CSL Limited
- Grifols S.A
- Kedrion S.P.A
- LFB S.A
- Octapharma AG
- Pfizer Inc
- Bayer Healthcare Pharmaceuticals LLC
- Among others
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Speak to Our Expert: https://growthplusreports.com/inquiry/speak-analyst/immunoglobulin-market/7774
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
